SynthesisInternational journal of clinical and experimental pathology2015
Clinicopathologic and prognostic significance of p21 (Cip1/Waf1) expression in bladder cancer.
Synthesis in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Immunohistochemical markers in predicting behavior of bladder urothelial carcinoma.Caspian journal of internal medicine · 2024Article
- Enhanced Cytotoxic Activity of PEGylated Curcumin Derivatives: Synthesis, Structure-Activity Evaluation, and Biological Activity.International journal of molecular sciences · 2023Article
- Tumor suppressive role of microRNA-139-5p in bone marrow mesenchymal stem cells-derived extracellular vesicles in bladder cancer through regulation of the KIF3A/p21 axis.Cell death & disease · 2022Article
- Circular RNAs: A Promising Biomarker for Endometrial Cancer.Cancer management and research · 2021Review
- CDKN1A/p21American journal of cancer research · 2021Article
- CRISPR-CasRx Targeting LncRNA LINC00341 Inhibits Tumor Cell GrowthFrontiers in molecular biosciences · 2021Article
- Article
- ROC-1, P21 and CAIX as markers of tumor aggressiveness in bladder carcinoma in Egyptian patients.Diagnostic pathology · 2020Article
- CRISPR-Cas13-Mediated Knockdown of lncRNA-GACAT3 Inhibited Cell Proliferation and Motility, and Induced Apoptosis by Increasing p21, Bax, and E-Cadherin Expression in Bladder Cancer.Frontiers in molecular biosciences · 2020Article
- Harnessing citizen science through mobile phone technology to screen for immunohistochemical biomarkers in bladder cancer.British journal of cancer · 2018Article
- miR372 Promotes Progression of Liver Cancer Cells by Upregulating erbB-2 through Enhancement of YB-1.Molecular therapy. Nucleic acids · 2018Article
- Circular RNA circ-ITCH inhibits bladder cancer progression by sponging miR-17/miR-224 and regulating p21, PTEN expression.Molecular cancer · 2018Article
- HistoneH3 demethylase JMJD2A promotes growth of liver cancer cells through up-regulating miR372.Oncotarget · 2017Article
- Review
- Urinary Bladder Cancer: Biomarkers and Target Therapy, New Era for More Attention.Oncology reviews · 2016Review
- Promoter-associated endogenous and exogenous small RNAs suppress human bladder cancer cell metastasis by activating p21 (CIP1/WAF1) expression.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Bladder Cancer-related microRNAs With In Vivo Efficacy in Preclinical Models.Cancer diagnosis & prognosisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent studies have shown that altered expression p21 is shown to associate with tumorigenesis and tumor progression. To investigate the clinicopathological significance and prognostic value of p21 in bladder cancer (BCa). A total of 48 patients with BCa were included in this study. The correlation between p21 expression and clinicopathologic features and survival was studied. Also, a meta-analysis was performed to investigate the relationship between the p21 and BCa survival. Low p21 expression was detected both in tumor tissues compared with adjacent normal tissues. The expression of p21 was closely associated with advanced pathologic TNM stage (P=0.001) and tumor grade (P=0.013). Moreover, patients with low p21 expression had shorter recurrence-free survival (P=0.016) and overall survival rates (P=0.039). Multivariate Cox regression analysis revealed that p21 low expression was an independent prognostic factor for recurrence free survival (P=0.03). Additionally, our meta-analysis. The available outcome data from six articles were examined. A meta-analysis of the HR indicated a significantly poor overall survival (OS, HR: 1.75, 95% CI: 1.38-2.21), recurrence free survival (RFS, HR: 1.83, 95% CI: 1.57-2.15), progression free survival (PFS, HR: 2.02, 95% CI: 1.48-2.75), and cancer specific survival (CSS, HR: 1.89, 95% CI: 1.53-2.33) in patients with low expression levels of p21. Our present results indicated that low p21 expression predicated tumor recurrence and poor prognosis in bladder cancer.
Indexed as
Identifiers
26191193PMC4503065W1020189353What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.